


**Name: Suzetrigine Cat#: EX-A7354**

Target: Sodium Channel

Pathway: Membrane Transporter/Ion Channel

Chemical Structure:



|               |  |  |  |
|---------------|--|--|--|
| Chemical Name | 4-[[[(2R,3S,4S,5R)-3-(3,4-Difluoro-2-methoxyphenyl)tetrahydro-4,5-dimethyl-5-(trifluoromethyl)-2-furanyl]carbonyl]amino]-2-pyridinecarboxamide |  |  |
|---------------|--|--|--|

|                  |  |          |   |
|------------------|--|----------|---|
| Molecular Weight | 473.3932   | Storage  | 3 years -20°C powder                            |
| Formula          | C <sub>21</sub> H <sub>20</sub> F <sub>5</sub> N <sub>3</sub> O <sub>4</sub> |          | 6 months -80°C in solvent<br>Away from moisture |
| CAS No.          | 2649467-58-1   | Synonyms | VX-548  |

|                     |  |         |  |
|---------------------|--|---------|--|
| Solubility (25°C) * | In vitro                                       | DMSO    | Soluble in DMSO<br>>=100mg/mL ( Need ultrasonic) |
|                     |  | Ethanol | N/A  |
|                     |  | Water   | N/A  |
|                     | In vivo (should be freshly prepared each time) |         |  |

\* <1 mg/ml means slightly soluble or insoluble.  
 \* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

## Preparing Stock Solutions:

| Concentration | Mass   | 1 mg  | 5 mg      | 10 mg      |
|---------------|--------|-------|-----------|------------|
|               | Volume |       |           |            |
| 1 mM          | 1 mM   | 1 mM  | 2.1124 mL | 10.5621 mL |
| 5 mM          | 5 mM   | 5 mM  | 0.4225 mL | 2.1124 mL  |
| 10 mM         | 10 mM  | 10 mM | 0.2112 mL | 1.0562 mL  |

DMSO : \*The above data is based on the product molecular weight 473.39.

## Biological Activities:

|                    |   |
|--------------------|---|
| <b>Description</b> | Suzetrigine (VX-548) is an orally active and highly selective Nav1.8 inhibitor that acts as an analgesic. Suzetrigine is also a blocker of sodium channel protein type 10 subunit alpha <sup>[1][2]</sup> . |
|--------------------|---|

|                   |  |
|-------------------|--|
| <b>References</b> | [1]. <a href="#">Jones J, et al. Selective Inhibition of Nav1.8 with VX-548 for Acute Pain. N Engl J Med. 2023 Aug 3;389(5):393-405.</a><br>[2]. <a href="#">WHO Drug Information-World Health Organization (WHO).</a> |
|-------------------|--|